XML 35 R21.htm IDEA: XBRL DOCUMENT v3.23.2
SEGMENT AND ENTERPRISE-WIDE INFORMATION
 3 Months Ended
Jul. 01, 2023
Segment Reporting [Abstract]  
SEGMENT AND ENTERPRISE-WIDE INFORMATION
15. SEGMENT AND ENTERPRISE-WIDE INFORMATION

The Company determines its reportable segments by first identifying its operating segments, and then by assessing whether any components of these segments constitute a business for which discrete financial information is available and where segment management regularly reviews the operating results of that component. The Company’s reporting structure aligns with its operating structure of three global business units and the information that is regularly reviewed by the Company’s chief operating decision maker.

The Company’s reportable and operating segments are as follows:
•Plasma
•Blood Center
•Hospital

Management measures and evaluates the operating segments based on operating income. Management excludes certain corporate expenses from segment operating income. In addition, certain amounts that management considers to be non-recurring or non-operational are excluded from segment operating income because management evaluates the operating results of the segments excluding such items. These items include integration and transaction costs, amortization of acquired intangible assets, restructuring costs, restructuring related costs, digital transformation costs related to the upgrade of our enterprise resource planning system, impairments, accelerated device depreciation and related costs, costs related to compliance with the European Union Medical Device Regulation (“MDR”) and In Vitro Diagnostic Regulation (“IVDR”) and unusual or infrequent and material litigation-related charges. Although these amounts are excluded from segment operating income, as applicable, they are included in the reconciliations that follow. Management measures and evaluates the Company’s net revenues and operating income using internally derived standard currency exchange rates that remain constant from year to year; therefore, segment information is presented on this basis.

Selected information by reportable segment is presented below:
Three Months Ended
(In thousands)July 1,
2023		July 2,
2022
Net revenues
Plasma$138,482 $103,042 
Blood Center67,306 66,573 
Hospital99,536 89,184 
Net revenues by business unit305,324 258,799 
Service (1)
5,764 5,137 
Effect of exchange rates244 (2,478)
Net revenues$311,332 $261,458 
(1) Reflects revenue for service, maintenance and parts
Three Months Ended
(In thousands)July 1,
2023		July 2,
2022
Segment operating income
Plasma$75,698 $55,126 
Blood Center26,283 30,377 
Hospital40,943 34,722 
Segment operating income142,924 120,225 
  Corporate expenses (1)
(75,309)(81,584)
  Effect of exchange rates2,613 6,245 
  Integration and transaction costs(1,115)758 
  Amortization of acquired intangible assets(7,473)(8,367)
  Restructuring costs11 44 
  Restructuring related costs(2,204)(3,522)
  Digital transformation costs(3,705)— 
  Impairment of assets and PCS2 related charges141 350 
  MDR and IVDR costs(1,166)(3,186)
  Litigation-related charges(1,058)(196)
Operating income$53,659 $30,767 
(1) Reflects shared service expenses including quality and regulatory, customer and field service, research and development, manufacturing and supply chain, as well as other corporate support functions.

Management reviews revenue based on the reportable segments noted above. Although these reportable segments are primarily product-based, they differ from the Company’s product line revenues for Plasma products and services and Blood Center products and services. Specifically, the Blood Center reportable segment includes plasma products utilized for collection in blood centers primarily for transfusion purposes. Additionally, product line revenues also include service revenues which are excluded from the reportable segments.

Net revenues by business unit are as follows:
  Three Months Ended
(In thousands)July 1,
2023		July 2,
2022
 Plasma$138,610 $102,381 
Whole Blood20,040 19,595 
Apheresis47,300 46,099 
 Blood Center67,340 65,694 
Hemostasis Management37,820 33,497 
Vascular Closure37,620 29,568 
Other(1)
24,168 25,429 
 Hospital99,608 88,494 
Net business unit revenues305,558 256,569 
Service5,774 4,889 
Net revenues$311,332 $261,458 
(1) Other includes the Cell Salvage and Transfusion Management product lines of the Hospital business unit.
Net revenues generated in the Company’s principle operating regions on a reported basis are as follows:
Three Months Ended
(In thousands)July 1,
2023		July 2,
2022
United States$237,073 $181,996 
Japan11,773 13,878 
Europe39,387 40,457 
Rest of Asia22,040 24,424 
Other1,059 703 
Net revenues$311,332 $261,458